Skip to main content

Press releases | August 5, 2025

Fried Frank advised Citi as financial advisor to STAAR Surgical Company (NASDAQ: STAA) (STAAR) in its definitive merger agreement with Alcon (SIX/NYSE: ALC). Under the terms of the agreement, Alcon will purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value. Alcon is a Swiss-American pharmaceutical and medical device company specializing in eye care products. STAAR is a provider of implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. The transaction is anticipated to close within approximately one year. 

The Fried Frank team was led by corporate partner Roy Tannenbaum. 


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.